|
4Q11 |
4Q12 |
4Q13 |
4Q14 |
4Q15 |
4Q16 |
4Q17 |
4Q18 |
Create chart |
| Net sales revenues |
769,544 |
930,692 |
1,008,148 |
1,040,033 |
955,009 |
1,028,665 |
1,102,632 |
1,263,377 |
|
| Change in Fair Value of Biological Assets |
53,519 |
39,933 |
40,863 |
32,770 |
21,188 |
43,135 |
93,603 |
27,201 |
|
| Cost of Goods Sold |
-461,395 |
-511,732 |
-553,961 |
-638,522 |
-606,619 |
-633,043 |
-695,393 |
-859,665 |
|
| Depreciation / Amortization / exhaustion |
-72,737 |
-79,555 |
-89,093 |
-112,197 |
-98,876 |
-108,874 |
-99,996 |
-104,142 |
|
| Exhaustion of biological assets |
-32,518 |
-47,121 |
-57,071 |
-48,974 |
-29,947 |
-64,596 |
-31,284 |
-39,805 |
|
| Gross Profit |
256,413 |
332,217 |
348,886 |
273,110 |
240,755 |
265,287 |
369,562 |
286,966 |
|
| Selling Expenses |
-88,454 |
-97,631 |
-114,812 |
-135,191 |
-148,906 |
-154,070 |
-172,905 |
-190,806 |
|
| General and Administrative Expenses |
-28,072 |
-28,612 |
-32,294 |
-34,057 |
-43,182 |
-34,318 |
-37,117 |
-52,079 |
|
| Management Compensation |
-3,068 |
-3,256 |
-3,829 |
-4,031 |
-3,361 |
-3,715 |
-4,048 |
-4,100 |
|
| Other Operating Compensation |
-5,601 |
13,254 |
-62,301 |
32,155 |
-15,182 |
32,734 |
-20,671 |
-278,619 |
|
| Equity income from subsidiaries |
null |
2,536 |
2,019 |
- |
0 |
-265,287 |
0 |
0 |
|
| Operating Profit before Financial Income and Equity |
131,218 |
218,508 |
137,669 |
131,986 |
30,124 |
105,918 |
134,821 |
-238,638 |
|
| Financial Income |
23,417 |
20,632 |
29,661 |
48,569 |
37,123 |
28,674 |
27,600 |
17,384 |
|
| Financial Expenses |
-54,627 |
-49,638 |
-67,213 |
-94,420 |
-94,631 |
-107,475 |
-81,885 |
-48,379 |
|
| Income Before Income Tax and Social Contribution |
100,008 |
189,502 |
100,117 |
86,135 |
-27,384 |
27,117 |
80,536 |
-269,633 |
|
| Income and social contribution taxes - current |
4,552 |
-26,587 |
-16,809 |
-19,491 |
-7,619 |
-18,321 |
-7,940 |
3,850 |
|
| Income Tax and Social Contribution - Deferred |
-25,173 |
-11,237 |
-18,758 |
23,545 |
89,359 |
16,411 |
12,022 |
123,824 |
|
| Effect profit from discontinued operation |
null |
-2,278 |
5,739 |
null |
null |
- |
0 |
0 |
|
| Net Income |
79,387 |
149,400 |
70,289 |
90,189 |
54,356 |
25,207 |
84,618 |
-141,959 |
|
| Recurring Net Income |
79,387 |
145,060 |
118,124 |
85,716 |
76,239 |
6,463 |
112,936 |
151,269 |
|
| Recurring EBITDA |
188,781 |
301,480 |
304,512 |
267,252 |
185,343 |
217,107 |
228,870 |
236,836 |
|
| EBITDA Margin |
24.5 % |
32.4 % |
30.2 % |
25.7 % |
19.4 % |
21.1 % |
20.8 % |
18.7 % |
|
* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex
**from 1Q 12 the data does not include discontinued operation, Deca Piazza
